A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
← catalyst calendarNCT07647328 · readout in 924 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With ICON plc.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
150estimated
Sites
89
Countries
France, Germany, Italy +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-15 | actual | When the study began enrolling |
| Primary completion | 2029-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ER-Positive HER2-Negative Breast Cancer
Interventions
- Drug: Camizestrant — also filed as AZD9833
- Drug: Ribociclib — also filed as KISQALI®
Primary outcome
what the primary-completion date above is the date OFEfficacy of camizestrant and ribociclib by time to next treatment (TTNT)
measured Following first dose of study treatment until earliest of subsequent therapy, death and 2 years after first dose of study treatment.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed